The current standard first-line therapy for unresectable advanced or recurrent GC is fluoropyrimidine plus either cisplatin [2] or oxaliplatin [3] for HER2-negative AGC, and the addition of trastuzumab to fluoropyrimidine plus platinum therapy [4] for HER2-positive AGC. This evidence concerns the gene ERBB2 and gastric cancer.